# US 2013/0156780 A1 · Annexin 1 Antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156780 A1
- Document ID: US20130156780A1
- Status: Published application
- Kind: A1
- Application number: 13/702,593
- Filed: 2011-06-09
- Published: 2013-06-20
- Earliest claimed: 2010-06-09
- Assignees: Queen Mary & Westfield College, University of London
- Inventors: Fulvio D'Acquisto; Mauro Perretti
- Web page: https://patentgrep.com/patent/US20130156780A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.

## Claims

### Claim 1

A specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence SEQ ID NO:8.

### Claim 2 (depends on 1)

A specific binding molecule comprising the Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3 of the specific binding molecule as claimed in claim 1 or an amino acid sequence at least 70% identical to each of the respective CDRs.

### Claim 3 (depends on 2)

A specific binding molecule as claimed in claim 2 comprising Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which
(SEQ ID NO: 2)
VLCDR1 is KASENVVTYVS
(SEQ ID NO: 3)
VLCDR2 is GASNRYT
(SEQ ID NO: 4)
VLCDR3 is GQGYSYPYT
(SEQ ID NO: 5)
VHCDR1 is GYTFTNYWIG
(SEQ ID NO: 6)
VHCDR2 is DIYPGGDYTNYNEKFKG
(SEQ ID NO: 7)
VHCDR3 is WGLGYYFDY
or an amino acid sequence at least 70% identical thereto.

### Claim 4 (depends on 1)

A specific binding molecule as claimed in claim 1 wherein the specific binding molecule is an antibody or fragment thereof.

### Claim 5 (depends on 4)

A specific binding molecule as claimed in claim 4 wherein the antibody is a monoclonal antibody.

### Claim 6 (depends on 5)

A specific binding molecule as claimed in claim 5 wherein the monoclonal antibody is humanized.

### Claim 7 (depends on 4)

A specific binding molecule as claimed in claim 4 wherein the fragment is a Fab, F(ab′)2 or Fv fragment or an scFv molecule.

### Claim 8 (depends on 1)

A specific binding molecule as claimed in claim 1 comprising a polypeptide having an amino acid sequence SEQ ID NO:15 and/or SEQ ID NO:19.

### Claim 9 (depends on 1)

A specific binding molecule as claimed in claim 1 produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301.

### Claim 10

A hybridoma cell line which produces a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence SEQ ID NO:8.

### Claim 11 (depends on 10)

A hybridoma cell line as claimed in claim 10 deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a specific binding molecule as claimed in claim 1.

### Claim 13 (depends on 12)

A pharmaceutical composition as claimed in claim 12, further comprising another therapeutically active agent.

### Claim at position 14

14-21. (canceled)

### Claim 22 (depends on 1)

A method for the treatment of a T cell-mediated disease in a subject in need thereof, comprising administering to the subject a specific binding molecule as claimed in claim 1.

### Claim 23 (depends on 22)

The method as claimed in claim 22 wherein said T cell-mediated disease is selected from the group consisting of graft-versus-host disease, graft rejection, atherosclerosis, HIV, AIDS, psoriasis, miscarriage, and autoimmune diseases.

### Claim 24 (depends on 23)

The method as claimed in claim 23 wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE), Addison's disease, Grave's disease, scleroderma, polymyositis, diabetes, autoimmune uveoretinitis, ulcerative colitis, pemphigus vulgaris, inflammatory bowel disease, autoimmune thyroiditis, uveitis, Behcet's disease, and Sjogren's syndrome.

### Claim 25 (depends on 23)

The method as claimed in claim 23 wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).

### Claim 26 (depends on 23)

The method as claimed in claim 23 wherein said autoimmune disease is rheumatoid arthritis (RA) or multiple sclerosis (MS).

### Claim 27 (depends on 22)

The method as claimed in claim 22 wherein said T cell-mediated disease is selected from the group consisting of atherosclerosis, HIV, AIDS, and psoriasis.